Clinical Trials | November 14, 2025
Roche reports breakthrough phase III results for investigational multiple sclerosis drug
Fenebrutinib targets cells in the immune system known as B cells and microglia
Fenebrutinib targets cells in the immune system known as B cells and microglia
The ALLEGORY study demonstrated statistically significant improvements in key measures, including British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) response
Test delivers results in just 18 minutes, enabling faster laboratory workflows and patient management during outbreaks
Key secondary endpoints also demonstrated statistically significant and clinically meaningful benefits with Gazyva
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
Vamikibart is the first targeted, non-steroid treatment designed to address the underlying inflammation driving UME
New test expands access to early Alzheimer’s assessment, streamlining diagnostic pathways and improving referral efficiency
Roche will unveil the primary results from the phase III evERA Breast Cancer study evaluating giredestrant
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Combination reduced the risk of disease progression or death by 46% and risk of death by 27% in pivotal phase III IMforte study
Subscribe To Our Newsletter & Stay Updated
